In accordance with ASX Listing Rule 17.1, Zelira Therapeutics Limited (‘the Company’, ASX: ZLD) requests the granting of a trading halt in ZLD’s ordinary securities listed on the Australian Securities Exchange (ASX). The Company provides the following information in relation to the request:
1.The trading halt is requested pending an announcement by the Company in relation to interimresults of its Insomnia Clinical Trial;
2.The Company requests an immediate trading halt and anticipates that the trading halt remain in place until the earlier of the commencement of trading on Wednesday, 19 February 2020or the making of an announcement in respect to interim results of its Insomnia Clinical Trial; and
3.ZLD confirms that it is not aware of any reason why a trading halt should not be granted or any other information necessary to inform the market about the trading halt.
ZLD Price at posting:
5.8¢ Sentiment: Hold Disclosure: Held
